AZ struck out in May in trying to expand Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.
The policy revelation shows just how eager Novartis is in addressing some latest ethics shortfalls.
Merck is already in phase 3 testing for its next-generation pneumococcal vaccine, and Pfizer's CFO said his company is "all in" on advancing its…
AstraZeneca’s latest data on its triple-combination COPD candidate may not do much to help it against rival GlaxoSmithKline.
Astellas is reupping its sponsorship of ABC’s “Dancing With the Stars,” partnering with former pro boxer and TV personality Laila Ali.
The new eczema data came a month ahead of an expected FDA decision on the drug's fate in asthma.
Sticker prices in drug ads might be off the table again, thanks to some in the U.S. House of Representatives.
Flonase, Claritin and Nasacort are the most-clicked brands in search ads for allergies, according to a new Kantar Media study,
Sanofi and Regeneron are ready to wheel and deal if they win the FDA's blessing to tout their cholesterol drug Praluent's cardiovascular benefits.
There's a dearth of treatments for early-stage lung cancer, so J&J is raising a flag in the field to hunt for sparks of innovation.
